In January 2025, the US Food and Drug Administration (FDA) authorized the marketing of nicotine pouches to individuals aged 21 years and older. However, the use of nicotine pouches among teens appears ...

Vaping, Juuling, cloud chasing – we have all most likely heard of electronic cigarettes or vapes. With so many new terms and devices being pushed to market, it can feel hard to keep track of the ...

Nicotine is a highly addictive stimulant that is found in tobacco products such as cigarettes, cigars and chewing tobacco.

Researchers at the University of Southern California found the popularity of nicotine pouches is soaring, especially among ...

And over the past several years, they’ve skyrocketed in popularity.

Smoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved ...

Achieve Life Sciences is partnering with marketing company Omnicom to lead Achieve's commercial launch of a potential new treatment for nicotine dependence in the U.S. The pharmaceutical company on ...

The tax on pouches, including brands such as Zyn, is expected to generate $12 million per year for the state. But the company that makes Zyn argues that taxing pouches will drive Rhode Islanders back ...

In a zebrafish model that mimics human obesity and craving behaviors, SKNY-1 demonstrated weight loss, suppression of appetite and craving for high-calorie diets, and reversal of nicotine ... The drug ...

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.

To be very clear: Anyone taking nicotine to treat brain fog (like me) is still very much experimenting. There are no protocols or prescribed doses approved by the Food and Drug Administration.

Group (NASDAQ:XXII) is developing another reduced nicotine cigarette, with a goal to receive approval from the U.S. Food and ...